Crescent Grove Advisors LLC lessened its holdings in shares of Moderna, Inc. (NASDAQ:MRNA – Get Rating) by 26.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,386 shares of the company’s stock after selling 500 shares during the quarter. Crescent Grove Advisors LLC’s holdings in Moderna were worth $249,000 at the end of the most recent reporting period.
Other institutional investors have also recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD lifted its stake in shares of Moderna by 89.9% in the 3rd quarter. Price T Rowe Associates Inc. MD now owns 6,443,409 shares of the company’s stock valued at $761,934,000 after purchasing an additional 3,051,035 shares during the last quarter. Theleme Partners LLP boosted its stake in shares of Moderna by 0.3% during the 2nd quarter. Theleme Partners LLP now owns 6,354,406 shares of the company’s stock worth $907,727,000 after acquiring an additional 17,466 shares in the last quarter. Renaissance Technologies LLC increased its holdings in shares of Moderna by 108.2% during the 1st quarter. Renaissance Technologies LLC now owns 3,818,180 shares of the company’s stock valued at $657,720,000 after acquiring an additional 1,984,458 shares during the last quarter. Northern Trust Corp raised its stake in shares of Moderna by 0.6% in the 1st quarter. Northern Trust Corp now owns 3,503,325 shares of the company’s stock valued at $603,483,000 after acquiring an additional 20,416 shares in the last quarter. Finally, FMR LLC lifted its holdings in Moderna by 20.5% in the 2nd quarter. FMR LLC now owns 2,706,654 shares of the company’s stock worth $386,645,000 after purchasing an additional 459,992 shares during the last quarter. 63.11% of the stock is currently owned by institutional investors and hedge funds.
Moderna Trading Down 1.6 %
Shares of MRNA stock opened at $152.10 on Wednesday. The firm has a fifty day moving average of $166.18 and a 200-day moving average of $160.94. The stock has a market cap of $58.66 billion, a price-to-earnings ratio of 7.62 and a beta of 1.70. Moderna, Inc. has a 52-week low of $115.03 and a 52-week high of $217.25. The company has a debt-to-equity ratio of 0.05, a quick ratio of 2.54 and a current ratio of 2.73.
Insider Activity at Moderna
In other Moderna news, insider Juan Andres sold 2,000 shares of the stock in a transaction on Wednesday, December 28th. The stock was sold at an average price of $180.00, for a total transaction of $360,000.00. Following the completion of the transaction, the insider now directly owns 12,803 shares in the company, valued at $2,304,540. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, insider Shannon Thyme Klinger sold 459 shares of the business’s stock in a transaction that occurred on Thursday, March 2nd. The stock was sold at an average price of $136.43, for a total value of $62,621.37. Following the transaction, the insider now directly owns 5,243 shares of the company’s stock, valued at approximately $715,302.49. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Juan Andres sold 2,000 shares of the firm’s stock in a transaction on Wednesday, December 28th. The shares were sold at an average price of $180.00, for a total value of $360,000.00. Following the sale, the insider now directly owns 12,803 shares of the company’s stock, valued at $2,304,540. The disclosure for this sale can be found here. Insiders have sold a total of 534,337 shares of company stock valued at $92,331,032 in the last 90 days. 17.30% of the stock is owned by corporate insiders.
Analyst Ratings Changes
MRNA has been the topic of several analyst reports. SVB Leerink downgraded Moderna from a “market perform” rating to an “underperform” rating and lowered their price target for the company from $111.00 to $93.00 in a report on Friday, February 24th. Royal Bank of Canada assumed coverage on shares of Moderna in a research report on Wednesday, March 1st. They set an “outperform” rating and a $200.00 target price for the company. TD Cowen raised Moderna from a “market perform” rating to an “outperform” rating and raised their price target for the company from $150.00 to $180.00 in a research report on Monday, March 13th. SVB Securities lowered Moderna from a “market perform” rating to an “underperform” rating and dropped their price objective for the stock from $111.00 to $93.00 in a research note on Friday, February 24th. Finally, Morgan Stanley decreased their target price on Moderna from $205.00 to $185.00 in a research note on Thursday, February 23rd. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $180.80.
Moderna Profile
Moderna, Inc engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.
Read More
- Get a free copy of the StockNews.com research report on Moderna (MRNA)
- Asana Stock Gap and Crap. Here’s Why
- On Holding AG Sprints Higher on Margin Expansion and Guidance
- Price Growth & Yield: For That Magical Combo, Leave the U.S.
- Game-Changing News For Tesla Investors
- DOW New Hghs Coming Sooner Than Later
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.
